{"id":15538,"date":"2023-08-02T23:33:00","date_gmt":"2023-08-02T15:33:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15538"},"modified":"2024-11-28T23:40:12","modified_gmt":"2024-11-28T15:40:12","slug":"mabwell-bioscience-secures-licensing-deals-for-denosumab-biosimilars-in-egypt-and-pakistan","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15538","title":{"rendered":"Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan"},"content":{"rendered":"\n

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062<\/a>) has announced separate licensing and commercialization agreements with a strategic business partner in Egypt and Pakistan pharmaceutical company Searle Co Ltd. These agreements grant local rights to Mabwell’s denosumab biosimilars, MAILISHU and 9MW0321.<\/p>\n\n\n\n

Denosumab Biosimilars and Their Impact on Fracture Risk Reduction<\/strong>
Denosumab, a novel RANKL inhibitor originally developed by Amgen, is currently marketed in China by BeiGene. The drug has been shown to significantly reduce the risk of multiple fractures in patients, including vertebral, non-vertebral, and hip fractures. This makes the biosimilars an important addition to the treatment options for osteoporosis and other bone diseases.<\/p>\n\n\n\n

Regulatory Approvals and Market Access<\/strong>
MAILISHU, one of Mabwell’s denosumab biosimilars, received approval from the China National Medical Products Administration (NMPA) in March 2023. The other biosimilar, 9MW0321, has been filed for Marketing Authorization (MA) approval, indicating Mabwell’s commitment to expanding access to these critical therapies.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced separate licensing and commercialization agreements…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[43,118,2449,1129],"class_list":["post-15538","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biosimilars","tag-mabwell-bioscience","tag-searle","tag-sha-688062"],"yoast_head":"\nMabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced separate licensing and commercialization agreements with a strategic business partner in Egypt and Pakistan pharmaceutical company Searle Co Ltd. These agreements grant local rights to Mabwell's denosumab biosimilars, MAILISHU and 9MW0321.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15538\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15538\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-02T15:33:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-28T15:40:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15538#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15538\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan\",\"datePublished\":\"2023-08-02T15:33:00+00:00\",\"dateModified\":\"2024-11-28T15:40:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15538\"},\"wordCount\":167,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biosimilars\",\"Mabwell Bioscience\",\"Searle\",\"SHA: 688062\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15538#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15538\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15538\",\"name\":\"Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-02T15:33:00+00:00\",\"dateModified\":\"2024-11-28T15:40:12+00:00\",\"description\":\"China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced separate licensing and commercialization agreements with a strategic business partner in Egypt and Pakistan pharmaceutical company Searle Co Ltd. These agreements grant local rights to Mabwell's denosumab biosimilars, MAILISHU and 9MW0321.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15538#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15538\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15538#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan - Insight, China's Pharmaceutical Industry","description":"China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced separate licensing and commercialization agreements with a strategic business partner in Egypt and Pakistan pharmaceutical company Searle Co Ltd. These agreements grant local rights to Mabwell's denosumab biosimilars, MAILISHU and 9MW0321.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15538","og_locale":"en_US","og_type":"article","og_title":"Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15538","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-02T15:33:00+00:00","article_modified_time":"2024-11-28T15:40:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15538#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15538"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan","datePublished":"2023-08-02T15:33:00+00:00","dateModified":"2024-11-28T15:40:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15538"},"wordCount":167,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biosimilars","Mabwell Bioscience","Searle","SHA: 688062"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15538#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15538","url":"https:\/\/flcube.com\/?p=15538","name":"Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-02T15:33:00+00:00","dateModified":"2024-11-28T15:40:12+00:00","description":"China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced separate licensing and commercialization agreements with a strategic business partner in Egypt and Pakistan pharmaceutical company Searle Co Ltd. These agreements grant local rights to Mabwell's denosumab biosimilars, MAILISHU and 9MW0321.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15538#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15538"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15538#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15538"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15538\/revisions"}],"predecessor-version":[{"id":15540,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15538\/revisions\/15540"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}